Cargando…

High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer

BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheta, Heba, Abd El hafez, Amal, Saif, Maha, Elsergany, Alyaa R., Al emam, Doaa, Abdelrazik, Mahmoud Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore srl 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167402/
https://www.ncbi.nlm.nih.gov/pubmed/34042091
http://dx.doi.org/10.32074/1591-951X-217
_version_ 1783701683874824192
author Sheta, Heba
Abd El hafez, Amal
Saif, Maha
Elsergany, Alyaa R.
Al emam, Doaa
Abdelrazik, Mahmoud Mohamed
author_facet Sheta, Heba
Abd El hafez, Amal
Saif, Maha
Elsergany, Alyaa R.
Al emam, Doaa
Abdelrazik, Mahmoud Mohamed
author_sort Sheta, Heba
collection PubMed
description BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and disease-free survivals (OS, DFS) and patient’s outcome. METHODS: Patient’s socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-and low-FOXA1 expression groups using appropriate statistical methods. Kaplan-Meier method was used for survival analysis. RESULTS: FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing high- and low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and low-grade serous), type I EOC, limited tumor’s anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ≤ 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumor’s anatomical extent and tumor’s size (p ≤ 0.001, = 0.046 and = 0.023 respectively). CONCLUSION: FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker.
format Online
Article
Text
id pubmed-8167402
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Pacini Editore srl
record_format MEDLINE/PubMed
spelling pubmed-81674022021-07-08 High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer Sheta, Heba Abd El hafez, Amal Saif, Maha Elsergany, Alyaa R. Al emam, Doaa Abdelrazik, Mahmoud Mohamed Pathologica Original Article BACKGROUND: Forkhead box (FOX) A1 is a potential therapeutic biomarker that has been investigated in various human cancers. Limited data exist about FOXA1 biologic role in epithelial ovarian cancer (EOC). AIM: This study assessed FOXA1 immunohistochemical (IHC) expression and evaluated its association with clinico-pathological parameters in EOC including overall and disease-free survivals (OS, DFS) and patient’s outcome. METHODS: Patient’s socio-epidemiologic, clinical, radiological, laboratory, surgical, and follow-up data were collected. After histopathologic typing, grading and staging, FOXA1 IHC expression was scored in 98 EOC specimens. Clinico-pathological associations were investigated in high-and low-FOXA1 expression groups using appropriate statistical methods. Kaplan-Meier method was used for survival analysis. RESULTS: FOXA1 tumor cell nuclear staining was detected in 63.3% of EOC with weak, moderate and strong scores (28.6%, 12.2% and 22.5% respectively). Comparing high- and low-expression groups (34.7% and 65.3% respectively), high FOXA1 was associated with larger tumors, low mean serum CA-125, tumor histopathology (mucinous and low-grade serous), type I EOC, limited tumor’s anatomical extent, absence of nodal or distant metastases and omental nodules, earlier FIGO stages, non-recurrent tumors and survival advantage with longer and OS and DFS (all p ≤ 0.05). Independent predictors of high FOXA1 expression included: omental nodules, tumor’s anatomical extent and tumor’s size (p ≤ 0.001, = 0.046 and = 0.023 respectively). CONCLUSION: FOXA1 is frequently expressed in EOC notably mucinous and low-grade serous carcinomas in association with favorable prognostic clinico-pathological parameters and longer OS and DFS. It likely has a suppressor function in EOC and could be recommended as a prognostic and therapeutic biomarker. Pacini Editore srl 2021-04-01 /pmc/articles/PMC8167402/ /pubmed/34042091 http://dx.doi.org/10.32074/1591-951X-217 Text en © 2021 Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en
spellingShingle Original Article
Sheta, Heba
Abd El hafez, Amal
Saif, Maha
Elsergany, Alyaa R.
Al emam, Doaa
Abdelrazik, Mahmoud Mohamed
High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title_full High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title_fullStr High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title_full_unstemmed High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title_short High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
title_sort high foxa1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167402/
https://www.ncbi.nlm.nih.gov/pubmed/34042091
http://dx.doi.org/10.32074/1591-951X-217
work_keys_str_mv AT shetaheba highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer
AT abdelhafezamal highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer
AT saifmaha highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer
AT elserganyalyaar highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer
AT alemamdoaa highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer
AT abdelrazikmahmoudmohamed highfoxa1immunohistochemicalexpressionlevelassociateswithmucinoushistologyfavorableclinicopathologicalprognosticparametersandsurvivaladvantageinepithelialovariancancer